CURRENT VIEWS SUGGEST THAT acute or chronic stress, such as inflammation, may induce a switch in intestinal stem cells and progenitors (i.e., primitive cells) toward an oncogenic phenotype characterized by unregulated growth and resistance to apoptosis (58) . Patients with inflammatory bowel disease (IBD) have higher risk to develop colorectal cancer (CRC) within their lifetime. Probably associated with a genetic predisposition (55), inflammation is a major driver of colitisassociated CRC whose specific mechanisms are not well understood.
In the intestinal epithelium, protease-activated receptors (PARs) that belong to the G protein-coupled receptor family have been shown to regulate cell survival and proliferation (57) . PARs are cleaved by proteases leading to new PAR amino-terminus exposure that can bind intramolecularly and activate the receptor. Once activated, PARs trigger multiple signaling pathways through intracellular coupling to specific G protein subunits and to signal modulating proteins such as ␤-arrestin. Expression of PAR 1 and PAR 2 is increased in IBD (57) and CRC (10, 65) . Also, IBD-and CRC-derived tissues exhibit increased proteolytic activities of proteases such as thrombin and matrix metalloprotease 1 that activate PAR 1 and trypsin-like serine proteases, tissue factor, and matriptase, which activate PAR 2 (9, 47) . PAR 1 and PAR 2 are coexpressed in tumor cells, and they both promote IBD (23) and cancer progression (54) . Nevertheless, whether PAR 1 and/or PAR 2 affect normal and tumor colon stem/progenitor cell proliferation and survival is not defined yet.
Most patients with IBD who develop CRC have quiescent chronic inflammation associated with reepithelialization of colonic mucosa by abnormal clones giving multifocal dysplasia. Thus the survival of primitive intestinal epithelial cells promoted by proinflammatory mediators is critical in oncogenesis (19, 45) . In nonintestinal cells, PAR 2 has been shown to promote cell survival upon stress or inflammation (39, 42) . In CRC, PAR 2 activation is also protective (7, 24) . PAR 1 activation enhances cell survival of melanoma and breast cancer cells (38, 46) . Both protease receptors regulate prosurvival pathways such as ERK, Akt, and NF-B, but the final cell death or survival depends on the cell type, the amplitude, and duration of agonist exposure and the biaised agonism (35, 68) . Furthermore, the cross talk between PAR 1 and PAR 2 , or between PARs and the epidermal growth factor (EGF) receptor or integrins, could have distinct regulatory functions on cell survival and proliferation (1, 37) .
Glycogen synthase kinase-3␤ (GSK3␤) is a major serinethreonine kinase at the crossroad of metabolic, survival, and proliferation pathways that has been implicated in inflammation and malignant transformation (61, 66) . It is a regulator of NF-B and signal transducer and activator of transcription (Stat)-3, which play key roles in driving normal cells to an oncogenic phenotype (5, 50) . Also, GSK3␤ regulates the Wnt pathway, a major player in the CRC process, as well as epigenetic changes involved in intestinal wound healing (27, 41) . In CRC, GSK3␤ is overexpressed and overactivated (60) , controlling cell survival and therapeutic response (17, 18, 36) , as we have previously shown in leukemia (4, 13, 14) . However, how GSK3␤ is regulated in intestinal stem/progenitor cells and whether it could participate in PAR-dependent cell survival remains unknown.
We have previously shown that ␣ 5 ␤ 1 -integrins can trigger GSK3␤ activation in leukemic progenitors through a RACK1-PP2A pathway (4, 14) . In these conditions, GSK3␤ is activated through serine-9 dephosphorylation either directly by PP2A or secondary to PP2A-induced inhibition of Akt. Indeed, in leukemic progenitors, we found a clear correlation between nonactive Akt (Akt dephosphorylated at serine-473) and its active substrate GSK3␤ (GSK3␤ dephosphorylated at serine-9) (6). It is unknown if other receptors than integrins, and specifically PAR 1 and PAR 2 , activate GSK3␤ in stem/progenitor cells to favor their survival and potentially their malignant transformation.
Based on these considerations, our study aimed to determine whether PAR 1 and/or PAR 2 regulate normal and tumor colon stem/progenitor cell survival and ability to grow in threedimensional (3D) spheres and whether this is mediated by GSK3␤ activation. We used different models [normal or cancer cells, 2-dimensional (2D) or 3D cultures] to investigate whether the PAR-GSK3␤ relationship could be linked to the malignant transformation or to the adhesion of colon epithelial cells.
MATERIALS AND METHODS

Ethics statement
Human samples. Patients were included in the registered MICILIP study (Clinical trials no. NCT01990716) and gave written informed consent. The protocol was approved by the local ethic committee from Toulouse, France (Comité de Protection des Personnes Sud-Ouest et Outre-mer).
Animal samples. Animal samples complied with protocol agreement 12-U1043-NV-11, approved by the local ethic committee from Toulouse, France (animal care committee CEEA-122). Pharmacological inhibitors. SB-216763 and 6-bromoindirubin-3=-oxime (BIO) were from Tocris Bioscience (R&D Systems, Lille, France). Rho kinase inhibitor Y-27632 was from Sigma. Animals C57BL/6 male mice (6 wk old) were purchased from Janvier (Le Genest Saint Isle, France). C57BL/6 male mice deficient for PAR 2 were from the group of Lindner et al. (33) . In some experiments, C57BL/6 wild-type (WT) and PAR 2 knockout (KO) littermate male mice were used (Animal facilities, Anexplo platform; UMS US006/ INSERM, Toulouse, France). Animals were maintained in ventilated cages (4 mice/cage) in a specific pathogen-free room at 20 -24°C and relative humidity (40 -70%) with a 12:12-h light-dark cycle and given free access to food and water. In total 60 mice were included in this study. All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals of the European Council and were reported in accordance with the ARRIVE guidelines (29) . Animals were killed for abdominal laparotomy and colon sampling by a lethal overdose of intraperitoneal pentobarbital followed by cervical dislocation.
Antibodies and Pharmacological Inhibitors
Colons from Sox9-green fluorescent protein (GFP) or Lgr5-GFP mice were from the University of North Carolina (44, 56, 59) .
Cells
IEC-6 (ATCC-CRL-1592) and Caco-2 (ATCC-HTB-37; LGC Standards authentification certificate) cell lines (ATCC, LGC Standards, Molsheim, France) and CMT93 (ATCC-CCL-223) were cultured in Dulbecco's modified eagle's medium (DMEM catalog no. 31966 with Glutamax and 1 mM sodium pyruvate) supplemented with 100 U/ml penicillin/streptomycin and 10% fetal calf serum (FCS) without complement. Caco-2 culture medium was supplemented by 1% nonessential amino acids. All cell culture reagents were from Invitrogen.
Both IEC-6 and Caco-2 cell lines were cultured at 37°C and 5% CO 2 until reaching 90% confluence, and medium was changed every 2 days. Tests to rule out the presence of mycoplasmal contamination were performed. Cells were used for experiments before fourth passage after thawing (culture duration ϭ 1 mo with passage each week). In those culture conditions, IEC-6 and Caco-2 cells were undifferentiated (11, 64) .
CMT93 cell line deficient for PAR 2 was generated using Crispr/ Cas9 technology. CMT93 was electroporated with mouse PAR2 Crispr/Cas9 plasmid (ref. no. sc 420265; Santa Cruz). Transfected cells were sorted by fluorescence-activated cell sorter to isolate GFP-positive cells, from which clonal isolation and expansion were done. Functional calcium mobilization tests were performed to validate PAR 2 deficiency in clones. Briefly, CMT93 WT or invalidated for PAR2 were incubated with fluo 8 probe (Screen Quest Fluo-8 calcium AAT bioquest) for 30 min at 37°C and 20 min at room temperature. PAR2 or PAR1 agonist peptides (APs), namely SLIGRL-NH2 or TFLLR-NH2 (Genscript, Piscataway, NJ), were added to the cells. Immediately after, fluorescence was measured at an excitation wavelength of 460 -490 nm and emission wavelength of 515 nm. Calcium flux assays were performed in an automated plate reader (NOVOstar; BMG Labtech). Results are expressed as the ⌬F/F, representing the ratio of the fluorescence measurement of each recording to the baseline measurement (mean of the fluorescence intensity between 0 and 10 s).
Colonospheres and Tumor Spheroids
Colonospheres were obtained from murine crypts following the protocols previously described (48, 56) . Colon crypts were isolated from the 2/3 ends of descendant colon of C57BL/6 male mice (8 wk old). The colon was opened longitudinally, washed in phosphatebuffered saline (PBS), and incubated in chelation buffer (in mM: 5.6 Na 2HPO4, 8 KH2PO4, 96.2 NaCl, 1.6 KCl, 43.4 sucrose, 54.9 D-sorbitol, and 0.5 DL-1,4-dithiothreitol) plus 2 mM EDTA during 30 min under gentle rocking at 4°C. Supernatant was then removed, and colonic fragments were resuspended in cold chelation buffer by manual vigourous up and down shaking for 2 min. Supernatant was removed, and colonic fragments were further incubated in chelation buffer plus EDTA for 30 min at room temperature. Supernatant was removed, and colonic fragments resuspended in cold chelation buffer were shaken vigorously for 1 min. Supernatant containing crypts was collected through three steps of resuspension/shaking in cold chelation buffer. Crypts were pelleted (43 g, 5 min), processed for RT-PCR analysis, or resuspended in cold chelation buffer and passed through a 21-gauge needle to dissociate the bottom from the top of colon crypts. After being washed in cold chelation buffer and centrifuged at 43 g for 5 min, which allows for individual cells and small aggregates to be discarded, 1,000 bottom crypts were embedded in 25 l Matrigel (EHS sarcoma tumor matrix, growth factor reduced, phenol red free; BD Biosciences) and seeded in 48-well plates. Ten minutes after initiation of Matrigel polymerization at 37°C, 250 l DMEM F-12 supplemented with 100 U/ml penicillin/streptomycin, 10 mM HEPES, 2 mM Glutamax, N2 (1:100), B27 (1:50) (all from Thermo Fisher Scientific) and 1 mM N-acetylcysteine (Sigma, Saint-Quentin Fallavier, France), 100 ng/ml Wnt-3a (R&D Systems), 50 ng/ml EGF (GIBCO, Thermo Fisher Scientific), 100 ng/ml noggin (Peprotech, Neuilly sur Seine, France), and 1 g/ml R-spondin 1 (R&D Systems) were added.
Tumor spheroids were obtained from 1 ϫ 10 4 Caco-2 cells embedded in 4 l Matrigel seeded on top of 20 l polymerized Matrigel in 48-well plates (34) . Later (30 min), DMEM supplemented with 100 U/ml penicillin/streptomycin, 10% FCS, and nonessential amino acids was added for culture.
In 3D culture conditions, crypt epithelial cells and Caco-2 cells maintain their undifferentiated phenotype (43, 48) . Colonospheres and tumor spheroids were observed daily using an apotome microscope (HXP120; Zeiss Axio-observer) to follow their growth. After seeding (48 h), both normal and tumor 3D cultures showed round shape structures whose size increased until the 7th day where cultures were stopped or processed for passage. Medium was changed every 2 days.
For passage, colonospheres were incubated for 30 min with Cell Recovery solution (BD Transduction Laboratories, BD Biosciences, Le Pont de Claix, France) on ice. This step allows the dissociation of spheroids from Matrigel. Next, spheroids were gently resuspended in ice-cold BSA-coated tubes containing DMEM F-12 supplemented with HEPES, Glutamax, and penicillin/streptomycin as described above. After centrifugation (43 g, 10 min), spheroids were reembedded in Matrigel and cultured as described.
PAR Stimulation
PAR 1 and PAR2 activation was triggered by specific APs, TFLLR and SLIGRL from Genscript, respectively. One hundred micromolar APs or their reversed sequence used as controls (Genscript or Ezbiolab, Carmel, IN), both dissolved in Hanks' balanced salt solution, were added to the colonosphere and serum-starved (24 h) tumor spheroid cultures every day from 48 h of seeding. At day 6, colonospheres were counted at the microscope: around 70 colonospheres were counted in control wells. Tumor spheroids number was evaluated by both microscopy and colorimetric analysis (MTS tetrazolium compound; Promega, Madison, WI), given their high density. Spheroid counting was conducted through brightfield microscopy, and for each well of culture four quadrants were analyzed along the entire depth of the Matrigel layer. The size of colonospheres and tumor spheroids was evaluated after importation of apotome images in the Image J software: spheroids from 20 to 80 m were measured, and a threshold at 40 m was choosen to calculate variations in the different conditions of treatment. For Western blot, colonospheres from 14 wells were dissociated from Matrigel with Cell Recovery Solution at day 6 of culture, and pooled samples were washed three times in DMEM F-12 supplemented with HEPES, Glutamax, and penicillin/ streptomycin before denaturation in Laemmli sample buffer.
In 2D culture, IEC-6 and Caco-2 cells were seeded in 96-well (4 ϫ 10 4 cells) and 12-well (1 ϫ 10 6 cells) plates. After 24 h of serum starvation, cells were stimulated by 100 M (or various concentrations, as indicated) PAR 1 or PAR2 APs, or their controls. At 1 h of PAR stimulation, 12-well plates were processed to prepare cell lysates. Briefly, after a wash in PBS, cells were scraped in cold lysis buffer (20 mM Tris·HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM EDTA ϩ kinase/phosphatase/protease inhibitor cocktail). Samples were then shaken for 15 min at 4°C, further sonicated, and denatured in Laemmli sample buffer. Cells from 96-well plates were incubated with MTS at 24 h of PAR stimulation, and then the estimation of surviving cells was made by spectrometry (Varioskan Flash; Thermo Fisher Scientific).
Kinase Activity
Fifteen million Caco-2 cells at 80% confluence were serum starved and stimulated by 100 M PAR 1 or PAR2 APs as described above. After 1 h, cells were washed in cold PBS and scraped in cold lysis buffer (50 mM Tris·HCl, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 1 mM Na 3VO4, 1 mM NaF, 1 mM Na4P2O7, 1 mM EDTA ϩ kinase/phosphatase/protease inhibitor cocktail). After 20 min agitation on ice, lysates were centrifuged 15 min at 12,000 g at 4°C, and the supernatants were recovered for 30 min preclearing with protein G-Sepharose. Next, supernatants were incubated with 20 l GSK3␤ antibody for 2 h at 4°C. This was followed by an incubation with 50 l protein G-Sepharose for 2 h at 4°C. After one wash in lysis buffer and two washes in PBS, immune complexes were resuspended in 7 l of kinase buffer (Omnia Ser/Thr peptide 13 Kit; Life Technologies, Saint-Aubin, France). Next, the kinase assay was performed following the protocol indicated by the Omnia kit supplier: briefly, immunoprecipitated GSK3␤ (2 or 5 l) was incubated at 30°C with the Sox fluorophore-chelated substrate peptide in kinase reaction buffer containing ATP. Fluorescence intensity was recorded every 30 s for 60 min by measuring the absorbance at 485 nm in a 96-well plate (Varioskan, Thermo Fischer Scientific, Villebon sur Yvette, France). Equal amounts of immunoprecipitated GSK3␤ from the different assays were checked by Western blot.
RNA Interference
Caco-2 cells were trypsinized and incubated with 1 M human PAR 2 (F2RL1) small-interfering RNA (siRNA; Accell SMARTpool siRNA; GE Dharmacon, Lafayette, CO) in DMEM without serum in 12-well plates for 72 h at 37°C. Accell nontargeting pool was used as control. After, transfected cells were trypsinized and plated in Matrigel to form spheroids in the presence of 10% FCS, or lysed for RT-PCR analysis. Spheroids were observed until the 4th day of culture by microscopy and immune labeled with anti-PAR2, anti-PSer 9 GSK3␤, or anti-Ki-67 at 48 h.
RT-PCR
Total RNAs were extracted using Trizol (Invitrogen, Carlsbad, CA) or a NucleoSpin RNA/Protein kit (Macherey Nagel) according to the manufacturer's instructions and were reverse transcribed using the Maxima first-strand kit (Fermentas; Thermo Fisher Scientific). cDNA (50 -75 ng) was used as template for amplification quantitative PCR with the following specific primers: for human PAR 2 forward 5=-CAGTGGCACCATCCAAGGA-3= and reverse 5=-TGTGCCATCAACCTTACCAATAA-3=, for human PAR1 forward 5=-GCGGCCCGCTGTTGT-3= and reverse 5=-ATCTA-AGGTGGCATTTGTTGCTTT-3=, for human/mouse hypoxanthine guanine phosphoribosyltransferase (reference gene) forward 5=-TGGGAGGCCATCACATTGT-3= and reverse 5=-TCCAGCAG-GTCAGCAAAGAA-3=, for mouse dual-specificity phosphatase 6 (DUSP6) forward 5=-GTTCTACCTGGAAGGTGGCT-3= and reverse 5=-TCCGTTGCACTATTGGGGTC-3=. Quantitative PCR was prepared with LightCycler 480 DNA SYBR Green I Master reaction mix (Roche, Mannheim, Germany) and run in duplicate on a LightCycler 480 Instrument (Roche).
Immunoprecipitation and Western Blotting
CMT93 WT and CMT93 PAR 2 KO at confluence in 75-cm 2 flasks (10 ϫ 10 6 cells) were serum starved for 24 h and then stimulated for 1 h by 100 M PAR2 AP. After two washes in cold PBS plus Ca 2ϩ /Mg 2ϩ , cells were scraped in cold lysis buffer: 50 mM Tris HCl, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 1 mM sodium orthovanadate, 1 mM sodium fluoride, antiprotease cocktail (Roche), 2 mM phenylmethylsulfonyl fluoride, and 1 mM EDTA. After 20 min of incubation on ice, samples were centrifuged at 12,000 g for 15 min, 4°C. An aliquot of supernatant was reserved for total lysate control, and preclearing with protein A-Sepharose was processed before overnight incubation at 4°C with ␤-arrestin 2 (clone C16D9) or Akt (clone 11E7) antibodies. Next, protein A-Sepharose was added to samples for 2 h at 4°C under gentle agitation. After centrifugation, an aliquot of the supernatant was reserved for immunoprecipitation supernatant control, and, after one wash in cold lysis buffer and two washes in cold PBS, Laemmli sample buffer was added.
After sonication and boiling for 10 min, proteins were resolved on SDS-PAGE and transferred to nitrocellulose (membrane Hybond C-super; Merck Millipore). The membrane was blocked for 1 h at room temperature in Tris-buffer saline (TBS) containing 0.5% fat-free milk and bovine serum albumin (BSA; Sigma). Next, membranes were probed overnight at 4°C with the appropriate antibodies in TBS-milk-BSA supplemented with 0.05% Tween. After incubation for 1 h at room temperature with either anti-mouse or anti-rabbit IgG antibody coupled to horseradish peroxidase, detection was achieved using a chemiluminescent substrate (SuperSignal; Amersham Pharmacia Biotech).
Immunostaining
Human samples of colon mucosas were obtained from patients undergoing a surgical resection for colon cancer or diverticulosis at Toulouse University Hospital, France. Samples were collected away from the tumor or diverticulosis, in normal area.
Histological sections from frozen mice (male C57BL/6, 8 wk) or human colons in optimum-cutting temperature compound were prepared. Tissues were fixed with 4% formaldehyde. After three washes (3 ϫ 10 min) in PBS plus 0.5% Triton X-100 and 1% BSA, slides were incubated overnight in a humid chamber with primary antibodies in PBS-Triton X-100-BSA. After three washes in PBS-Triton X-100-BSA, slides were then incubated with appropriate secondary fluorescent-coupled antibodies for 2 h at room temperature. Slides were finally washed three times in PBS, mounted in Prolong Gold-DAPI (Invitrogen Molecular Probes), and analyzed by confocal laser scanning using Zeiss LSM710 (Leica Microsystems, Heerbrugg, Germany).
For immunocytostaining, spheroids (colonospheres and tumor spheroids) were seeded in an eight-well Lab-Tek (Thermo Fisher Scientific). Spheroid culture conditions were as described above for 48-well plate seeding. Spheroids were fixed in 2% paraformaldehyde (20 min), washed three times in PBS (15 min), and then permeabilized in PBS plus 0.5% Triton X-100 (20 min). After two washes in PBS plus 100 mM glycine (20 min), blocking solution (7.7 mM NaN 3, 1% BSA, 0.2% Triton X-100, and 0.05% Tween 20, in PBS) was added for 90 min. Primary antibody was incubated overnight at 4°C. After three washes in blocking solution (15 min), secondary antibody was incubated for 45 min. Next, after washes in PBS, slides were mounted in ProGold DAPI and observed by confocal laser scanning (Zeiss LSM710). Actin staining was performed by adding Acti-stain 670 (Cytoskeleton) for 30 min followed by three washes in PBS before mounting.
For each staining, controls were made in the same conditions with no antibody, secondary antibody only, mouse IgG2a isotype control (BD), or preimmune rabbit serum in conjunction with secondary antibodies, as well as staining in PAR 2 KO tissue. Of note, comparison of Ki-67 staining between WT and PAR2 KO colons was from littermate mice.
Statistical Analysis and Image Processing
Student's t-test was used for experiment analysis. Time-lapse image stacks from Apotome and confocal images were imported in Image J software for analysis.
RESULTS
PAR 1 and PAR 2 Are Expressed in Colon Stem/Progenitor Cells
We first investigated PAR expression in colon epithelial stem and progenitor cells. In human and mouse colons, PAR 1 and PAR 2 expression was detected in the entire crypt, including at the crypt bottom within the stem/progenitor cell zone immunoreactive for the cell adhesion receptor CD44 (Fig. 1A) . Furthermore, PAR 1 and PAR 2 were expressed in Sox9-EGFP-and Lgr5-EGFP-positive cells that were shown to correspond to multipotent self-renewing stem cells (3, 44) (Fig. 1B) . Localization analysis shows that PAR 1 and PAR 2 are mainly in apical location in cells of the crypt surface and in the basolateral position in bottom cells (Fig. 1C) .
To investigate whether PAR 1 and PAR 2 have similar or distinct regulatory effects in normal and tumor epithelial stem/ progenitor cells, we used two different 3D Matrigel-based culture systems that are more relevant than 2D cultures to study stem cell-related functions (51, 67) . The first one corresponds to ex vivo 3D culture of crypt bottoms of murine normal/ healthy colon that grow into multicellular structures called colonospheres and originate from stem/progenitor cell survival and expansion. The second model corresponds to in vitro 3D culture of dissociated single CRC Caco-2 cells whose fraction with stem cell-like abilities grows into multicellular structures that we will term here tumor spheroids. Confocal analysis showed that PAR 1 and PAR 2 are expressed in both colonospheres and Caco-2-derived tumor spheroids ( Fig. 2A) . Interestingly, PAR 1 and PAR 2 were also found mostly in basolateral location in spheroids (Fig. 2B) .
PAR 2 Specifically Inhibits Colonosphere and Tumor Spheroid Growth
To study the impact of PAR activation on normal and tumor colon epithelial stem/progenitor cell function, PAR 1 and PAR 2 APs or control peptides were added daily from day 2 to day 6 of 3D cultures. Number and size of both colonospheres and tumor spheroids treated with PAR 2 agonist were decreased compared with controls (Fig. 3, top and  bottom) . By contrast, when treated with PAR 1 AP, 3D structures were larger and the number of PAR 1 -stimulated colonospheres or tumor spheroids was increased compared with controls (Fig. 3, top and bottom) . These data suggest that PAR 1 and PAR 2 oppositely impact the growth of normal and tumor colon stem/progenitor cells. PAR 2 effects on colon epithelial cell proliferation were further assessed in colonospheres grown from PAR 2 -deficient (PAR 2 KO) mice and in tumor spheroids from Caco-2 cells treated with siRNA targeting PAR 2 (80% decrease of mRNA expression; Fig. 4A ). Importantly, expression of PAR 1 remains stable after PAR 2 knockdown (Fig. 4A) . As shown in Fig. 4B , the number of Ki-67-positive cells was increased in both normal and tumor PAR 2 -deficient spheroids compared with controls. Interestingly, an increase of Ki-67 staining was also measured in crypt bottoms of PAR 2 KO colons compared with WT, and associated with a decrease of the MAPK inhibitor DUSP6 [a major gene target of PAR 2 (52)] mRNA (Fig. 4C) .
Altogether these data suggest that PAR 2 activation inhibits both normal and tumor stem/progenitor cell ability to proliferate and give rise to colonospheres and tumor spheroid, respectively, whereas PAR 1 activation stimulates it.
PAR 2 Enhances Survival in Colon Epithelial Stem/Progenitor Cells
We next investigated whether PAR 2 could impact intestinal stem/progenitor cell survival. Indeed, after 6 days of culture, numbers of colonospheres derived from PAR 2 -deficient crypt units were significantly reduced compared with WT crypt units (Fig. 5A ). This suggests that loss of PAR 2 impairs colonosphere-forming ability. Moreover, PAR 1 stimulation did not rescue PAR 2 KO colonosphere numbers (Fig. 5A) . PAR1 and PAR2 differentially control the growth of colon spheroids. Colonospheres and tumor spheroids were incubated daily with 100 M AP specific for PAR1 or PAR2, or control peptides (Ct), during 6 days. Colonospheres and tumor spheroids were then counted at microscope and measured by Image J software. Representative microscope images and number/size variations of PAR-activated colonospheres and tumor spheroids are shown in top. Number of colonospheres is from two independent experiments performed in duplicate (mean Ϯ SE). Size of 14 -20 colonospheres was calculated for each condition. Statistical analysis of percentage variations in no. and size of colon spheroids is shown in bottom; n ϭ 3 independent experiments, compared with the treatment with the respective control peptides of PAR1 and PAR2 agonists: mean Ϯ SE. *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001. caspase-3 staining revealed a large number of apoptotic cells in PAR 2 -deficient colonospheres but not in control or PAR 2 -stimulated colonospheres (Fig. 5B) . These results strongly suggest that PAR 2 is crucial for colon stem/progenitor cell survival.
Impact of PAR 2 stimulation on cell survival was then investigated in 3D and 2D culture systems. First, after gentle dissociation and reembedding, we recovered 56 and 40% of control and PAR 1 -stimulated colonospheres, respectively (Fig. 5C ). However, 70% of PAR 2 -stimulated colonospheres were recovered after passaging (Fig. 5C) . Similarly, serum starvation led to a decrease in the survival of the nontransformed and immature IEC-6 intestinal epithelial cell line, which was partially but significantly prevented by PAR 2 stimulation (Fig. 5D ). This PAR 2 -mediated enhancement of cell survival was associated with a decrease of active caspase-3 expression in colonospheres and in IEC-6 cells (Fig. 5, E and F) . ϩ cells in crypt bottoms compared with 20 total cells/crypt bottom (counted with DAPI nuclear staining) from 9 crypts of 2 WT mice and 9 crypts of 2 PAR2 KO mice: mean Ϯ SE. ***P Ͻ 0.001. Quantitative PCR analysis of dual-specificity phosphatase 6 (DUSP6) mRNA from WT and PAR2 KO crypts is shown: mean Ϯ SE compared with WT, ***P Ͻ 0.001 of 2 independent experiments performed in triplicate. Together, these data indicate that PAR 2 promotes colon epithelial stem/progenitor cell survival.
PAR 2 Prosurvival Impact on Intestinal Epithelial Cells Is GSK3␤ Dependent
We then assessed whether GSK3␤ may be implicated in PAR 2 -induced epithelial cell survival. First, in serum-starved IEC-6 cells, pharmacological GSK3 inhibition counteracted the prosurvival effect of PAR 2 stimulation (Fig. 6A) . Furthermore, addition of GSK3 inhibitors (BIO or SB-216763) induced a significant decrease in the number of colonospheres and tumor spheroids (Fig. 6B) . Importantly, PAR 2 AP pretreatment enhanced the inhibitory effects of the GSK3 inhibitor BIO (Fig. 6B) .
Taken together, these data suggest that a PAR 2 -dependent GSK3␤ pathway sustains the survival of normal and tumor colon epithelial stem/progenitor cells.
PAR 2 But Not PAR 1 Activates GSK3␤ Through Its Serine-9 in Intestinal Epithelial Cells
Given the impact of GSK3 inhibition on spheroid survival, we assessed GSK3␤ activation status in colonospheres and tumor spheroids deficient for PAR 2 expression. PAR 2 -deficient colonospheres and tumor spheroids exhibited a strong immunoreactivity for the nonactive form of GSK3␤ (Ser-9-phosphorylated GSK3␤) compared with control (Fig. 7A) , suggesting that PAR 2 loss leads to GSK3␤ inactivation.
We then investigated the PAR 2 -GSK3␤ signaling pathway in nontransformed IEC-6 and Caco-2 cells and determined whether PAR 2 and/or PAR 1 can activate GSK3␤. We chose to use 2D cultures instead of 3D colonosphere and tumor spheroid cultures because of biological material quantity limitation in the latter system. Dose-response experiments at 1 h stimulation with PAR 1 or PAR 2 APs (Fig. 7B) showed that only PAR 2 AP at the dose of 100 M reproducibly triggered serine-9 dephosphorylation of GSK3␤, indicative of its activation. Of note, 100 M PAR 2 AP was the efficient concentration that we used in spheroid cultures. PAR 2 activation (1 h) did not impact the GSK3␤ tyrosine-216 phosphorylation site, which also activates GSK3␤ when phosphorylated, suggesting that PAR 2 -mediated activation of GSK3␤ may be specific to the serine-9 phosphorylation site in both IEC-6 and Caco-2 cells (Fig. 7B) . Consistent with these data, PAR 2 activation led to increased GSK3␤ kinase activity compared with control (Fig. 7C) . In contrast, : n ϭ 7 independent experiments performed in duplicate, mean Ϯ SE. *P Ͻ 0.05 and ***P Ͻ 0.001. B: 48 h after initial embedding in Matrigel, colonospheres and tumor spheroids were treated with 100 M PAR2 AP or control peptide for 1 h before addition of GSK3 inhibitors (0.5 M BIO or 12.5 M SB-216763) or 0.05% DMSO (vehicle): spheroids were counted at the microscope and compared with the control: n ϭ 3 independent experiments performed in duplicate, mean Ϯ SE. *P Ͻ 0.05 and **P Ͻ 0.01. PAR 1 activation (1 h) increased both P-Tyr 216 GSK3␤ (GSK3␤ activation) and serine-9 phosphorylation (GSK3␤ inhibition) of the kinase in IEC-6, and there was a similar trend in Caco-2 cells (Fig. 7B, right) . Consistent with this result, total GSK3␤ kinase activity was not increased upon PAR 1 stimulation compared with the nonstimulated control (Fig. 7C) .
We then investigated whether PARs regulate Akt, which is an upstream regulator of GSK3␤ activity. As shown in Fig. 7B , variations of the P-Ser 473 active form of Akt were similar to those of the serine-9 of GSK3␤, a potential Akt substrate. Indeed, both P-Ser 473 Akt and P-Ser 9 GSK3␤ were decreased upon PAR 2 stimulation, suggesting that the inactivation of Akt may be implicated in GSK3␤ activation. Accordingly, the P-Tyr 307 inactive form of phosphatase PP2A, which is an upstream regulator of both Akt and GSK3␤, was found decreased upon PAR 2 activation in both IEC-6 and Caco-2 cells (Fig. 7D) .
These results show that, in intestinal epithelial cells, PAR 2 but not PAR 1 activates GSK3␤ through serine-9 dephosphorylation.
A ␤-Arrestin2/PP2A/GSK3␤ Complex Supports the Cross Talk between PAR 2 and Rho Kinase in Intestinal Epithelial Cells
The above results suggested that GSK3␤ may be associated with Akt and PP2A in a complex downstream of PAR 2 . Other work (40) has previously demonstrated such complex in association with ␤-arrestin 2, a known partner of PAR 2 signaling. We decided to use the CMT93 cell line that we built deficient immunolabeling (yellow) of serine-9-phosphorylated GSK3␤ (inhibited form) in PAR2-deficient colonospheres and tumor spheroids compared with controls. Nuclear DNA staining with DAPI is shown. Representative of 3 independent experiments. B: nontransformed (IEC-6) and colorectal cancer [CRC (Caco-2)] intestinal epithelial cells were cultured in 2D and after serum starvation were stimulated by 100 M or various concentrations of AP specific for PAR1 or PAR2, or control peptides, for 1 h. GSK3␤ and Akt regulation was then studied by Western blot. Selected cropped blots from the same experiment and processed in the same gel electrophoresis are shown, and a broken line indicates arrangement. Densitometric analysis (right) of P-Ser 9 GSK3␤, P-Tyr 216 GSK3␤, and P-Ser 473 Akt blots from all experiments is indicated. Total GSK3␤ and Akt is shown as well as loading control (actin); n ϭ 6 compared with treatment with the respective control peptides of PAR1 and PAR2 agonists: mean Ϯ SE. *P Ͻ 0.05. C: measurement of GSK3␤ activity in Caco-2 cells stimulated 1 h by 100 M PAR1 or PAR2 APs. Right, equal amounts of GSK3␤ immunoprecipitated in the different conditions; n ϭ 3 independent experiments performed in duplicate compared with the treatment with the respective control peptides of PAR1 and PAR2 agonists: mean Ϯ SE. *P Ͻ 0.05. D: as in B, IEC-6 and Caco-2 cells were PAR2 stimulated (100 M AP), and P-Tyr for PAR 2 expression to investigate both roles of PAR 2 in basal and activated states on that potential signaling complex.
We first checked by calcium flux analysis that CMT93 PAR 2 KO did not respond to PAR 2 AP (Fig. 8A) . However, the PAR 2 KO cells remained responsive to PAR 1 AP (Fig. 8A) . Next, the measure of P-Ser 9 GSK3␤ in PAR 2 -stimulated CMT93 confirmed the specificity of PAR 2 -induced activation of GSK3␤ at 100 M AP compared with 50 M, and GSK3␤ activation (serine-9 dephosphorylation) was not induced in the absence of PAR 2 (Fig. 8B) .
The immunoprecipitation of ␤-arrestin 2 showed its constitutive association with GSK3␤ and PP2A by contrast with Akt, which was not present in this complex (Fig. 8C) . Under PAR 2 activation (100 M AP), inactive form of PP2A (P-Tyr 307 PP2A) was decreased in the arrestin complex (Fig. 8C) . Furthermore, PAR 2 deficiency induced a decrease of GSK3␤ association with ␤-arrestin 2 and an increase of the inactive PP2A in that complex (Fig. 8C) . Altogether, these data strongly suggest that, downstream of PAR 2 , a ␤-arrestin 2/PP2A/GSK3␤ complex controls GSK3␤ activation.
Our above results show that the PAR 2 -dependent activation of GSK3␤ may be crucial for cell survival in stress conditions such as serum starvation and deadhesion. It is known that these conditions implicate a reorganization of the cytoskeleton through the regulation of GTPases such as Rho. We have thus investigated the impact of Rho kinase inhibition on GSK3␤ activation in CMT93 cells. As shown in Fig. 8D , the inactive form of GSK3␤ (P-Ser 9 GSK3␤) was increased at both 50 or 100 M PAR 2 AP but not significantly changed in PAR 2 KO cells. These results show that Rho kinase inhibition switched the response to PAR 2 AP from activation to inhibition of GSK3␤. We further investigated the relationship between Rho kinase and PAR 2 -dependent regulation of GSK3␤ by performing immunoprecipitates of ␤-arrestin 2 and Akt from Rho kinase inhibitor-and PAR 2 AP-treated CMT93 cells. As shown in Fig.  8E , whereas P-Ser 9 GSK3␤ was not significantly changed in ␤-arrestin 2 complex, it was clearly increased by PAR 2 AP associated with Rho kinase inhibitor, even compared with the slight increase due to PAR 2 AP alone, in Akt immunoprecipitate. According to the above results, this indicates that Rho kinase inhibition has switched the PAR 2 regulation of GSK3␤ through its inhibition by Akt. Consistently, the activated form of Akt (P-Ser 473 Akt) was measured in these conditions (Fig.  8E) . Interestingly, whereas PP2A was not present in Akt immunoprecipitate, in ␤-arrestin 2 complex, its ubiquitinated and degraded forms seem to be produced under both treatments by PAR 2 AP and Rho kinase inhibitor (Fig. 8E) .
Altogether, our results show that a ␤-arrestin 2/PP2A/ GSK3␤ complex is regulated by both PAR 2 and Rho kinase in intestinal epithelial cells.
DISCUSSION
This study aimed to determine whether PAR 1 and/or PAR 2 impact normal and tumor colon stem/progenitor cells and whether this is mediated by GSK3␤. With the use of ex vivo/in vitro 3D cultures of murine whole crypts or single tumor epithelial Caco-2 cells, our work gives strong evidence for a dual role for PAR 2 in the regulation of stem/progenitor cell ability to grow into multicellular epithelial structures. On one hand, PAR 2 activation limits normal and tumor cell proliferation in 3D structures, but on the other hand PAR 2 is essential to sustain cell survival and stem/progenitor ability to grow into 3D structures. Our data further suggest that PAR 2 impact on stem/progenitor cell is mediated by GSK3␤ activation. Of interest, our work also shows that PAR 1 exerts opposite effects on stem/progenitor cell proliferation and survival and does not impact overall GSK3␤ activity.
Our results demonstrate that PAR 1 and PAR 2 are expressed in colon epithelial cells, including those at the bottom of the crypts. Colocalization of PAR 1 and PAR 2 with CD44, which is enriched in the stem cell zone, further demonstrates that intestinal stem and progenitor cells express the protease receptors. The role of PARs in stem cells is poorly documented (8) , and our result reinforces their potential interest. Nevertheless, further in-depth work with sorted stem cells or cell lineage tracing technology needs to be performed to definitively conclude on the role of PARs in stem cell regulation.
One of our main findings is the dual role for PAR 2 in the control of normal and tumor stem/progenitor cells. First, our data demonstrate that activation of PAR 2 limits both normal and tumor stem/progenitor cell ability to form colono/tumorspheres and that loss of PAR 2 activates cell proliferation. This strongly suggests that PAR 2 inhibits stem/progenitor cell expansion in the context of normal crypts and CRC. Our results showing a decrease of DUSP6 mRNA associated with increased Ki-67 staining in PAR 2 KO crypts compared with WT are in favor of this hypothesis. Nevertheless, in breast cancer cells, PAR 2 controls PAR 1 -driven tumorigenesis and the association between activated PAR 1 and Akt (25) . Such requirement of combined activities of PAR 2 and other receptors has also been observed in matriptase-driven squamous cell carcinogenesis (47) Another part of our results demonstrates that whole crypt units derived from PAR 2 -KO animals show impaired ability to give rise to colonospheres and that PAR 2 activation prevents caspase-3-mediated apoptosis. Despite the fact that we used essentially nonlittermate mice in this study, preliminary experiments with WT and PAR 2 KO littermate mice further confirm the deleterious effect of PAR 2 deficiency on colonosphere culture. This indicates that PAR 2 is essential to sustain stem/ progenitor cell survival, at least in a normal setting. Consistently, PAR 2 has been shown to have antiapoptotic and probarrier functions in different cell types (22, 30, 42) . Altogether our data seem to indicate that PAR 2 both favors stem/progenitor cell survival and limits their proliferation. It is thus tempting to speculate that PAR 2 may participate in stem cell quiescence.
In both nontransformed and tumor epithelial cells, our data show that activated PAR 1 and PAR 2 had opposite impact on GSK3␤ phosphorylation at serine-9 and tyrosine-216 and that only PAR 2 induced increased GSK3␤ activity. To our knowledge, this is the first evidence in intestinal epithelial cells demonstrating that a receptor, and more specifically PAR 2 , can activate GSK3␤. PAR 1 and PAR 2 differential impact on GSK3␤ activation further strengthens the concept that the two receptors exert distinct effects on intestinal epithelial cell functions and that the ratio PAR 1 /PAR 2 may function as a rheostat to finely regulate stem/progenitor cell functions via the GSK3␤ pathway.
Our findings demonstrate that, in intestinal epithelial cells, PAR 2 promotes cell survival via GSK3␤. In 3D culture, the PAR 2 -GSK3␤ pathway was constitutively activated. This could occur either through autocrine activation linked to cell adhesion (8, 16) or Matrigel-bound proteases (28) . The perinuclear localization of PAR 2 that we show in immunostaining experiments could result from constitutive internalization or from a reserve pool in the Golgi, suggesting that PAR 2 is in permanence activated and then degraded and must be synthesized de novo (2) .
Also, PAR 2 has been shown to promote cell adhesion via ␤ 1 -integrin (37), a putative marker of intestinal stem/progenitor cells (15) , and our prior work showed that ␤ 1 -integrin activation induced survival via GSK3␤ in leukemic progenitors (4) . In histological sections of crypt bottoms and 3D culture, PAR 2 seems to be mostly present in basolateral position where adherens junctions and GSK3␤ are located (21) . Conversely, PAR 2 is mainly apical in surface cells of the crypt. Because it has been shown different signaling pathways depending on PAR 2 basolateral or apical localization (31) , and particularly basolateral PAR 2 was critical for tight junctions regulation, it is tempting to speculate that, in intestinal stem/progenitor cells, PAR 2 activates GSK3␤ through a cross talk with ␤ 1 -integrin that can associate with E-cadherins (62) . Our data showing that Rho kinase controls a switch between GSK3␤ activation in ␤-arrestin 2 complex and GSK3␤ inhibition in Akt complex downstream of PAR 2 activation are in favor of this hypothesis. Of note ␤-arrestin mobilization has been shown to be a strong component of PAR 2 signaling cascades (20) and of a bidirectional cross talk with Rho impacting notably stress fiber formation and phosphatase and tensin homolog (12) . Conversely, GSK3␤ may also play a crucial role in the regulation of the epithelial barrier through the transcriptional regulation of adherens junction proteins (49) . GSK3␤-induced stimulation of cell adhesion could lead to enhanced cell survival. This is consistent with our data showing increased recovery of passaged spheroids after pretreatment by PAR 2 AP.
Altogether our data suggest that the PAR 2 -GSK3␤ signaling pathway limits stem/progenitor cell expansion but favors their survival in tight coordination with cell adhesion status (Fig. 9) . As a result, one can hypothesize that, in pathological situations associated with chronic activation of the PAR 2 -GSK3␤ pathway, this might result in impaired mucosal healing, and stem/ progenitor cell resistance to genotoxic insult, mutation accumulation, and acquisition of oncogenic properties. This would be particularly relevant in IBD that have been associated with PAR 2 and GSK3␤ (57, 63) . The PAR 2 /GSK3␤-induced stem cell survival and proliferation arrest, i.e., quiescence, could also participate in cancer stem cell resistance to therapy (32) .
In conclusion, this work identifies PAR 2 /GSK3␤ as a novel pathway that plays a critical role in the regulation of stem/ progenitor cell survival and proliferation in normal colon crypts and in tumors and whose deregulation is likely to be involved in IBD-associated defects in mucosal healing and oncogenic transformation.
